ZHEJIANG ORIENT GENE BIOTECH CO.,LTD Zhejiang Orient Gene Biotech Co.,Ltd Stock
Equities
688298
CNE100003RM8
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.25 CNY | +1.04% |
|
-0.40% | -23.80% |
| Sales 2021 | 10.17B 1.4B | Sales 2022 | 8.77B 1.21B | Capitalization | 12.95B 1.79B |
|---|---|---|---|---|---|
| Net income 2021 | 4.92B 679M | Net income 2022 | 2.07B 285M | EV / Sales 2021 | 2.1 x |
| Net cash position 2021 | 6.28B 867M | Net cash position 2022 | 7.68B 1.06B | EV / Sales 2022 | 0.6 x |
| P/E ratio 2021 |
5.62
x | P/E ratio 2022 |
6.26
x | Employees | 2,830 |
| Yield 2021 |
2.68% | Yield 2022 |
2.59% | Free-Float | 50.63% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.04% | ||
| 1 week | -0.40% | ||
| Current month | -9.92% | ||
| 1 month | -13.90% | ||
| 3 months | -11.18% | ||
| 6 months | -22.78% | ||
| Current year | -23.80% |
1 week
25.88
27.59
1 month
25.8831.82
Current year
25.0037.38
1 year
25.0051.77
3 years
25.00245.01
5 years
25.00245.01
10 years
25.00245.01
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Qiu Fang
CEO | Chief Executive Officer | 41 | 10-05-31 |
Xiao Liang Fang
CHM | Chairman | 66 | 05-11-30 |
Jin Hong Yu
DFI | Director of Finance/CFO | 52 | 13-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Lin
BRD | Director/Board Member | 58 | 17-04-17 |
Xiao Ping Han
BRD | Director/Board Member | 63 | 17-04-17 |
Xiao Liang Fang
CHM | Chairman | 66 | 05-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 12 M€ | -16.71% | - | |
| 0.03% | 11 M€ | +0.34% | ||
| 0.00% | 117 M€ | +0.83% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 27.25 | +1.04% | 1,129,264 |
| 24-04-22 | 26.97 | +2.47% | 1,363,161 |
| 24-04-19 | 26.32 | -2.70% | 1,746,710 |
| 24-04-18 | 27.05 | -1.71% | 1,308,400 |
| 24-04-17 | 27.52 | +0.58% | 1,451,576 |
End-of-day quote Shanghai S.E., April 22, 2024
More quotes
Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.80% | 758M | |
| -12.75% | 7.4B | |
| +2.77% | 5.47B | |
| -1.37% | 4.51B | |
| +3.89% | 4.42B | |
| -50.71% | 3.29B | |
| +9.29% | 2.66B | |
| -14.69% | 2.07B | |
| -2.82% | 1.68B | |
| -14.72% | 1.66B |
- Stock Market
- Equities
- 688298 Stock
